Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

RSS icon

Patients with PTSD less likely to take hypertension meds

Patients with post-traumatic stress disorder (PTSD) and hypertension were found to be significantly less adherent with their blood pressure medication that hypertensive patients with no PTSD symptoms, based on findings in a research letter published online Dec. 2 in JAMA Internal Medicine.

Thumbnail

Overview sets foundation for catheter-based mitral valve therapies

Four cardiovascular societies offered recommendations to help get use of transcatheter therapies for mitral regurgitation off on the right foot in an overview released Nov. 25.

CABG outshines PCI for long-term risk reduction

CABG offers a greater long-term benefit to patients with multivessel disease than PCI does, regardless of diabetes status, according to a meta-analysis published online Dec. 2 in JAMA Internal Medicine. CABG reduced the risk of death or MI but showed a trend toward excess strokes.

Increased thromboses noted in patients with HeartMate II LVAD

Patients treated with the HeartMate II left ventricular assist device (LVAD) may be at higher risk for device thrombosis, based on the findings of a study published online Nov. 27 in the New England Journal of Medicine. Researchers found an increase in the number of thromboses compared with the results of pre-approval clinical trials. 

Endurant II AAA Stent Graft from Medtronic delivers durable, consistent and proven outcomes in real-world setting

Chosen for nearly one out of every two endovascular abdominal aortic aneurysm (AAA) repairs worldwide, the Endurant II AAA stent graft system from Medtronic, Inc. (NYSE: MDT) continues to demonstrate long-term durability and consistent outcomes at three years in a real-world setting.

FDA removes restrictions on rosiglitazone

The FDA lifted prescribing and dispensing restrictions on the drug rosiglitazone, saying it did not pose increased cardiac risks compared with other diabetes medications.

Thumbnail

FDA approves Promus Premier stent system

The FDA has given Boston Scientific the green light to market its next-generation durable polymer drug-eluting stent in the U.S.

Xigduo (dapagliflozin and metformin hydrochloride) receives positive CHMP opinion in the European Union for the treatment of type 2 diabetes

AstraZeneca and Bristol-Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of Xigduo™ (dapagliflozin and metformin hydrochloride) for adults aged 18 and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their current metformin-based treatment regimen or who are currently being treated with the combination of dapgliflozin and metformin as separate tablets.

Displaying 7777 - 7784 of 10748

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.